NICE guidance on bortezomib monotherapy for the treatment of relapsed myeloma
Bortezomib monotherapy is recommended as an option for myeloma patients who have relapsed after having received one prior treatment and who have undergone, or are not eligible for high-dose chemotherapy and stem cell transplantation.